We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RAIN Rain Oncology Inc

0.06 (5.71%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 151,667
Bid Price 0.99
Ask Price 1.11
News -
Day High 1.12


52 Week Range


Day Low 1.04
Company Name Stock Ticker Symbol Market Type
Rain Oncology Inc RAIN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.06 5.71% 1.11 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.06 1.04 1.12 1.11 1.05
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
724 151,667 $ 1.08 $ 163,268 - 0.82 - 14.48
Last Trade Time Type Quantity Stock Price Currency
19:58:31 formt 900 $ 1.11 USD

Rain Oncology Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
40.74M 36.38M - 0 -75.72M -2.08 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Rain Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No RAIN Message Board. Create One! See More Posts on RAIN Message Board See More Message Board Posts

Historical RAIN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.051.120.991.0578,7110.065.71%
1 Month1.121.14440.991.08106,822-0.01-0.89%
3 Months0.961.14440.821.00167,3450.1515.63%
6 Months1.101.480.821.20434,4130.010.91%
1 Year7.7414.480.822.58548,240-6.63-85.66%
3 Years22.1023.900.824.65283,638-20.99-94.98%
5 Years22.1023.900.824.65283,638-20.99-94.98%

Rain Oncology Description

Rain Therapeutics Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |